...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Impact of epoetin |[beta]| on quality of life in patients with malignant disease
【24h】

Impact of epoetin |[beta]| on quality of life in patients with malignant disease

机译：依泊汀|β|的影响恶性疾病患者的生活质量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This open-label, prospective study was conducted to compare the impact of epoetin β vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]11?g?dl?1) were randomised to a 12-week treatment with s.c. epoetin β (initial dose 150?IU?kg?1 three times weekly) or standard care. Transfusions were recommended for both groups at an Hb threshold of 8.5?g?dl?1. The primary efficacy variables were improvement in QoL as measured using the Short-Form-36 physical component summary (SF-36 PCS) score and the Functional Assessment of Cancer Therapy fatigue and anaemia subscales (FACT-F and FACT-An). A visual analogue scale (VAS) was also used as a global QoL measure. Clinical response was defined as a 2?g?dl?1 increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin β than with standard care (Pβ (P=0.076). Epoetin β significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P?1 were significantly predictive of response (OR 2.496, 95% CI: 1.21–5.13). Epoetin β therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.
机译：这项开放性，前瞻性研究旨在比较依泊汀β与标准护理对淋巴样或实体瘤恶性肿瘤贫血患者的生活质量（QoL）的影响。总共262名贫血患者（血红蛋白[Hb] 11？g？dl？1）被随机分配为s.c.治疗12周。依泊汀β（每周三剂初始剂量150？IU？kg？1）或标准护理。两组均建议以Hb阈值8.5？g？dl？1输血。主要疗效变量是使用Short-Form-36物理成分摘要（SF-36 PCS）评分和癌症治疗疲劳和贫血子量表的功能评估（FACT-F和FACT-An）测量的QoL改善。视觉模拟量表（VAS）也用作全局QoL量度。临床反应定义为在治疗的最初4周后Hb水平升高2？g？dl？1，而无需输血。依泊汀β的SF-36 PCS，FACT-F和VAS评分的最终访视变化基线显着高于标准护理（Pβ（P = 0.076）。依泊汀β相对于标准护理显着增加了Hb浓度（回复者：47 ％vs 13％; P？1可以显着预测反应（OR 2.496，95％CI：1.21-5.13）与标准治疗相比，依波替丁β疗法对实体瘤和淋巴恶性肿瘤贫血患者的QoL显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号